Press Release Details

Stereotaxis Reports 2021 Full Year Financial Results

03/03/22 at 9:00 AM EST

ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021.

“In 2021 we delivered significant revenue growth, drove a resurgence in adoption of robotics, advanced a broad wave of transformational innovations, and maintained financial discipline,” said David Fischel, Chairman and CEO.

“Renewed global adoption of robotic systems drove revenue growth of 32% for the year. We sold seven systems during 2021, the majority to hospitals establishing new robotic programs. We begin 2022 with purchase orders for four robotic systems and an expectation of multiple additional near-term orders that should drive revenue growth for this year. However, replacement activity remains below normalized levels with multiple opportunities delayed predominantly due to hospital construction supply chain and labor issues.”

“Stereotaxis is methodically advancing a robust innovation pipeline including a novel accessible robot, proprietary ablation catheters, vascular navigation devices, and an operating room connectivity solution. We expect regulatory submissions and initial commercial launches for all these within the next year and a half. Collectively, they serve as the foundational product ecosystem for a preeminent medical robotics company which can broadly transform endovascular interventions.”

“Concurrent with our commercial and technological progress, we are enhancing our infrastructure and team. We established a new headquarters and manufacturing facility that will support many years of growth. This progress is made while remaining prudent with shareholder capital. Stereotaxis starts the year with $40 million in cash and a modest controlled operating loss as we invest in innovation and growth.”

2021 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2021 totaled $8.2 million, representing growth of 21% from $6.8 million in the prior year fourth quarter. System revenue was $2.3 million with recurring revenue of $5.7 million, compared to $0.7 million and $5.9 million, respectively, in the prior year fourth quarter. Revenue for the full year 2021 totaled $35.0 million with growth of 32% from $26.6 million in 2020. System revenue of $11.2 million increased from $3.6 million in the prior year reflecting increasing adoption of our Genesis RMN systems. Recurring revenue of $22.9 million increased 4% from the prior year reflecting a partial recovery of procedure volumes.

Gross margin for the fourth quarter and full year 2021 were approximately 72% and 66% of revenue, respectively. Operating expenses in the fourth quarter were $9.3 million. Excluding $2.6 million in non-cash stock compensation expense, adjusted operating expenses in the current quarter were $6.7 million, compared to the prior year adjusted operating expenses of $5.7 million. Adjusted operating expenses for the full year 2021 were $26.9 million, up from $22.6 million in the prior year.

Operating loss and net loss for the fourth quarter of 2021 were both approximately ($3.4) million, compared to ($1.2) million for both in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($0.8) million, compared to ($0.4) million for both in the previous year. For the full year 2021, adjusted operating loss of ($3.6) million and adjusted net loss of ($1.4) million compared to ($3.6) million and ($3.5) million, respectively, in the prior year. Net loss in the current year reflects a favorable $2.2 million adjustment for the forgiveness of the Paycheck Protection Loan. Negative free cash flow for the full year 2021 was ($4.3) million, compared to ($3.6) million for the full year 2020.

Cash Balance and Liquidity
At December 31, 2021, Stereotaxis had cash and cash equivalents, including restricted cash, of $40.1 million and no debt.

Forward Looking Expectations
Stereotaxis anticipates revenue growth for the year driven by continued commercial adoption of the Genesis RMN system and stable recurring revenue. System revenue for the year will be primarily recognized in the second half of the year based on current customer schedules. Stereotaxis expects to modestly grow operating expenses with continued investment in key growth drivers, while maintaining a robust balance sheet that allows it to reach profitability without the need for additional financings. Stereotaxis is methodically establishing the product ecosystems that allow for significant future growth in electrophysiology and the broader field of endovascular surgery.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, March 3, 2022, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-866-409-1555 (US and Canada) or 1-313-209-4906 (International) and give the participant pass code 7498243. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer


  Three Months Ended
December 31,
  Year Ended
December 31,
    2021       2020       2021       2020  
Systems $ 2,337,624     $ 660,510     $ 11,167,676     $ 3,626,284  
Disposables, service and accessories   5,656,276       5,917,716       22,867,066       22,017,631  
Sublease   246,530       246,530       986,120       986,120  
Total revenue   8,240,430       6,824,756       35,020,862       26,630,035  
Cost of revenue:              
Systems   1,326,595       461,440       7,526,575       3,715,416  
Disposables, service and accessories   718,077       894,625       3,276,491       2,962,710  
Sublease   246,530       246,530       986,120       986,120  
Total cost of revenue   2,291,202       1,602,595       11,789,186       7,664,246  
Gross margin   5,949,228       5,222,161       23,231,676       18,965,789  
Operating expenses:              
Research and development   2,614,645       2,098,161       10,198,553       8,136,914  
Sales and marketing   3,045,968       2,898,472       11,948,068       11,178,325  
General and administrative   3,638,398       1,402,138       13,973,498       6,364,365  
Total operating expenses   9,299,011       6,398,771       36,120,119       25,679,604  
Operating loss   (3,349,783 )     (1,176,610 )     (12,888,443 )     (6,713,815 )
Interest (expense) income, net   (4,486 )     (4,240 )     (10,071 )     67,356  
Gain on extinguishment of debt   -       -       2,182,891       -  
Net loss $ (3,354,269 )   $ (1,180,850 )   $ (10,715,623 )   $ (6,646,459 )
Cumulative dividend on convertible preferred stock   (338,565 )     (340,471 )     (1,345,031 )     (1,369,421 )
Net loss attributable to common stockholders $ (3,692,834 )   $ (1,521,321 )   $ (12,060,654 )   $ (8,015,880 )
Net loss per share attributed to common stockholders:              
Basic $ (0.05 )   $ (0.02 )   $ (0.16 )   $ (0.11 )
Diluted $ (0.05 )   $ (0.02 )   $ (0.16 )   $ (0.11 )
Weighted average number of common shares and equivalents:              
Basic   75,801,866       74,954,091       75,558,233       72,746,268  
Diluted   75,801,866       74,954,091       75,558,233       72,746,268  

  December 31,
  December 31,
Current assets:      
Cash and cash equivalents $ 38,738,591     $ 43,939,512  
Restricted cash - current   454,268       -  
Compensating cash arrangement   -       250,620  
Accounts receivable, net of allowance of $179,913 and $123,614 at 2021 and 2020, respectively   5,405,860       3,515,136  
Inventories, net   4,433,394       3,295,457  
Prepaid expenses and other current assets   2,356,190       1,716,014  
Total current assets   51,388,303       52,716,739  
Property and equipment, net   2,631,891       195,129  
Restricted cash   951,563       -  
Operating lease right-of-use assets   5,734,775       2,235,442  
Other assets   278,154       308,515  
Total assets $ 60,984,686     $ 55,455,825  
Liabilities and stockholders' equity      
Current liabilities:      
Short-term debt $ -     $ 1,185,058  
Accounts payable   4,188,471       1,608,636  
Accrued liabilities   2,528,189       3,209,235  
Deferred revenue   6,276,781       5,282,770  
Current portion of operating lease liabilities   268,121       2,287,487  
Total current liabilities   13,261,562       13,573,186  
Long-term debt   -       973,252  
Long-term deferred revenue   2,238,150       548,915  
Operating lease liabilities   5,842,456       -  
Other liabilities   218,582       131,231  
Total liabilities   21,560,750       15,226,584  
Series A - Convertible preferred stock:      
Convertible preferred stock, Series A, par value $0.001; 22,387 and 22,513 shares outstanding at 2021 and 2020, respectively   5,583,768       5,605,323  
Stockholders' equity:      
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2021 and 2020   5,610       5,610  
Common stock, par value $0.001; 300,000,000 shares authorized, 74,618,240 and 73,694,203 shares issued at 2021 and 2020, respectively   74,618       73,694  
Additional paid-in capital   532,640,795       522,709,846  
Treasury stock, 4,015 shares at 2021 and 2020   (205,999 )     (205,999 )
Accumulated deficit   (498,674,856 )     (487,959,233 )
Total stockholders' equity   33,840,168       34,623,918  
Total liabilities and stockholders' equity $ 60,984,686     $ 55,455,825  

Primary Logo

Source: Stereotaxis, Inc.

Innovation Day